A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
In this 24-week study, spirapril antihypertensive effect and organo-protection was assessed inpatients with metabolic syndrome (MS) and arterial hypertension (AH). Parameters of 24-hour blood pressure (BP) monitoring (systolic and diastolic BP - 24 hours, daytime, nighttime) and pulse BP were significantly higher in MS patients than in AH individuals. Seventy-five per cent of MS patients had pathological circadian BP profile, with non-dippers' prevalence. In the same group, more advanced targetdoi:10.15829/1560-4071-2007-4-37-43 doaj:3aaf7f59d6e74bf39e787727c3f4bfd6 fatcat:qvea3d4mgbeirexzf6xqibt7he